In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.
nucleasesmedical
Enzymes that cut, trim or join nucleic acids (DNA or RNA), acting like molecular scissors that recognize specific genetic sequences and break or rejoin the chemical backbone. They are foundational tools in biotechnology for gene editing, diagnostics, and some therapeutics, so their properties, patents, manufacturing demands and regulatory pathways can affect a company’s product prospects, costs, and competitive position.
aavmedical
AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.
excisionmedical
Removal of tissue or a lesion by cutting it out, usually during a surgical procedure; it can range from taking out a small growth to removing a larger area of diseased tissue. Investors care because excision outcomes, complication rates, recovery time and related reimbursement affect demand for medical devices, surgical tools, hospital services and drug therapies—think of it as how the success and cost of a repair job influence the market for the tools and services used.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
DURHAM, N.C.--(BUSINESS WIRE)--
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the second quarter 2026 and provide a business update on Thursday, August 6, 2026.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of clinical stage in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination (removing a genome e.g. viral DNA such as in the Company’s PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company’s PBGENE-DMD program) and gene insertion (inserting DNA into gene to cause expression/add function).
